Activation of syk in peripheral blood B cells in patients with rheumatoid arthritis: A potential target for abatacept therapy

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 63-73

  Iwata, Shigeru ^a   Nakayamada, Shingo ^a   Fukuyo, Shunsuke ^a   Kubo, Satoshi ^a   Yunoue, Naoki ^a   Wang, Sheau Pey ^a   Yoshikawa, Maiko ^a   Saito, Kazuyoshi ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; GOLIMUMAB; METHOTREXATE; PROTEIN KINASE SYK; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; PROTEIN TYROSINE KINASE; TYRO3 PROTEIN, HUMAN;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD; DAS28; DISEASE ACTIVITY; DISEASE DURATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; AGED; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, HELPER-INDUCER; TREATMENT OUTCOME;

EID: 84919904707     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38895     Document Type: Article

References (49)

1. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
2. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
3. Taniguchi T, Kobayashi T, Kondo J, Takahashi K, Nakamura H, Suzuki J, et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem 1991; 266: 15790-6.
4. Wong WS, Leong KP,. Tyrosine kinase inhibitors: a new approach for asthma. Biochim Biophys Acta 2004; 1697: 53-69.
5. Beaven MA, Baumgartner RA,. Downstream signals initiated in mast cells by Fc-RI and other receptors. Curr Opin Immunol 1996; 8: 766-72.
6. Meltzer EO, Berkowitz RB, Grossbard EB,. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005; 115: 791-6.
7. Bajpai M,. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 2009; 12: 174-85.
8. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB,. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009; 113: 3154-60.
9. Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006; 317: 571-8.
10. Wossning T, Herzog S, Kohler F, Meixlsperger S, Kulathu Y, Mittler G, et al. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med 2006; 203: 2829-40.
11. Stadanlick JE, Kaileh M, Karnell FG, Scholz JL, Miller JP, Quinn WJ III, et al. Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling. Nat Immunol 2008; 9: 1379-87.
12. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A,. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-7.
13. Rudnicka W, Burakowski T, Warnawin E, Jastrzebska M, Bik M, Kontny E, et al. Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis patients. Eur J Immunol 2009; 39: 1211-20.
14. Iwata S, Yamaoka K, Niiro H, Nakano K, Wang SP, Akashi K, et al. Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. J Allergy Clin Immunol 2012; 129: 1594-601.
15. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi JI, Kaibara N, et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1299-304.
16. Sato K,. Th17 cells and rheumatoid arthritis-from the standpoint of osteoclast differentiation. Allergol Int 2008; 57: 109-14.
17. Crotty S,. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011; 29: 621-63.
18. Wang J, Shan Y, Jiang Z, Feng J, Li C, Ma L, et al. High frequencies of activated B cells and follicular helper T cells are correlated with disease activity in patients with new onset rheumatoid arthritis. Clin Exp Immunol 2013; 174: 212-20.
19. Nakayamada S, Kanno Y, Takahashi H, Jankovic D, Lu KT, Johnson TA, et al. Early Th1 cell differentiation is marked by a Tfh cell-like transition. Immunity 2011; 35: 919-31.
20. Nakayamada S, Takahashi H, Kanno Y, O'Shea JJ,. Helper T cell diversity and plasticity. Curr Opin Immunol 2012; 24: 297-302.
21. Mellor AL, Munn DH,. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20: 469-73.
22. Mellor AL, Munn DH,. Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003; 170: 5809-13.
23. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, et al. Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171: 1652-5.
24. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792-5.
25. Cabrian KM, Berry KK, Shuford WW, Mittler RS, Rodgers JN, Linsley PS,. Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig. Transplant Proc 1996; 28: 3261-2.
26. Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis 2012; 71: 1815-9.
27. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
28. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
29. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
30. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
31. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
32. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
33. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
34. Roll P, Dorner T, Tony HP,. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566-75.
35. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP,. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2377-86.
36. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-90.
37. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I,. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009; 45: 144-58.
38. De la Torre I, Moura RA, Leandro MJ, Edwards J, Cambridge G,. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy [published erratum appears in Ann Rheum Dis 2011;70:1350]. Ann Rheum Dis 2010; 69: 2181-8.
39. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62: 1273-9.
40. Henneken M, Dorner T, Burmester GR, Berek C,. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2005; 7: 1001-13.
41. Van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 2232-41.
42. Amara K, Steen J, Murray F, Morbach H, Fernandez-Rodriguez BM, Joshua V, et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013; 210: 445-55.
43. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122: 1791-802.
44. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63: 337-45.
45. Karampetsou MP, Andonopoulos AP, Liossis SN,. Treatment with TNFα blockers induces phenotypical and functional aberrations in peripheral B cells. Clin Immunol 2011; 140: 8-17.
46. Platt AM, Gibson VB, Patakas A, Benson RA, Nadler SG, Brewer JM, et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010; 185: 1558-67.
47. Schwartzberg PL, Mueller KL, Qi H, Cannons JL,. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol 2009; 9: 39-46.
48. De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 299-302.
49. Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial) [published erratum appears in Ann Rheum Dis 2011 Aug;70:1519]. Ann Rheum Dis 2010; 69: 510-6.